EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient

Grégoire Cullot, Valérie Lagarde, Jean-Michel Cayuela, Valérie Prouzet-Mauléon, Béatrice Turcq, Yosr Hicheri, Lydia Roy, Thorsten Braun, Marie-Joelle Mozziconacci, Anne-Sophie Alary, Stéphanie Dulucq

Annals of Hematology · 2025

DOI: 10.1007/s00277-024-06142-8 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, 2025. Verfasst von Grégoire Cullot und 10 weiteren Autor:innen. Beteiligte Einrichtung: Univ. Bordeaux, INSERM, BRIC, U1312, Bordeaux, France. gregoire.cullot@biol.ethz.ch. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Fusion Proteins, bcr-abl, Mutation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss Federal Institute of Technology Zurich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia patients largely benefit from an expanding tyrosine kinase inhibitors (TKIs) toolbox that has improved the outcome of both diseases. However, TKI success is continuously challenged by mutation-driven acquired resistance and therefore, close monitoring of clonal genetic diversity is necessary to ensure proper clinical management and adequate response to treatment. Here, we report the case of a ponatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) patient harboring a BCR::ABL1 p.I293_K294insSLLRD mutation. Using in vitro proliferation assays on newly generated Ba/F3 cell lines, we confirmed that the mutation confers moderate resistance to ponatinib, and to imatinib and nilotinib. In contrast, BCR::ABL1 SLLRD Ba/F3 cells remain highly sensitive to dasatinib. Unexpectedly, the insertion also provides resistance to asciminib with no inhibitory effect up to 1000 nM. Based on predicted structural models, we speculate that the p.I293_K294insSLLRD disrupts the interaction between the SH3 domain and the kinase domain, shifting the equilibrium toward the active conformation. This shift confers resistance to TKIs that preferentially bind to the inactive conformation, as well as to the allosteric asciminib inhibitor. However, the mutation retains sensitivity to dasatinib, which targets the active form of the kinase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmPrecursor Cell Lymphoblastic Leukemia-LymphomaFusion Proteins, bcr-ablMutationHumansProtein Kinase InhibitorsImidazolesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCell Line, TumorPyridazinesNiacinamidePyrazolesProto-Oncogene Proteins c-abl

Stichwörter der Autor:innen

ALLBCR::ABL1CMLCancer resistanceInsertion mutationTyrosine kinase inhibitor

Substanzen

Fusion Proteins, bcr-ablasciminibProtein Kinase InhibitorsponatinibImidazolesBCR-ABL1 fusion protein, humanPyridazinesABL1 protein, humanNiacinamidePyrazoles

Autor:innen und Institutionen

  • Univ. Bordeaux, INSERM, BRIC, U1312, Bordeaux, France. gregoire.cullot@biol.ethz.ch.
  • Department of Biology, ETH Zurich, Zurich, Switzerland. gregoire.cullot@biol.ethz.ch.
  • Univ. Bordeaux, INSERM, BRIC, U1312, Bordeaux, France.
  • Laboratory of Hematology, Saint-Louis Hospital, Assistance Publique-Hopitaux de Paris, Université de Paris, University Paris Diderot, Paris, France.
  • Fi-LMC Group, Léon Bérard Center, Lyon, France.
  • CRISP'edit, TBMCore, CNRS UAR3427, INSERM US005, Univ. Bordeaux, Bordeaux, France.

Förderung

  • Swiss Federal Institute of Technology Zurich

Zitieren

APA

Cullot, G., Lagarde, V., Cayuela, J. M., Prouzet-Mauléon, V., Turcq, B., Hicheri, Y., Roy, L., Braun, T., Mozziconacci, M. J., Alary, A. S., & Dulucq, S. (2025). Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient. Annals of Hematology. https://doi.org/10.1007/s00277-024-06142-8

Vancouver

Cullot G, Lagarde V, Cayuela JM, Prouzet-Mauléon V, Turcq B, Hicheri Y, et al. Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient. Annals of Hematology. 2025. doi:10.1007/s00277-024-06142-8

BibTeX
@article{Cullot2025,
  author = {Cullot, Grégoire and Lagarde, Valérie and Cayuela, Jean-Michel and Prouzet-Mauléon, Valérie and Turcq, Béatrice and Hicheri, Yosr and Roy, Lydia and Braun, Thorsten and Mozziconacci, Marie-Joelle and Alary, Anne-Sophie and Dulucq, Stéphanie},
  title = {Asciminib resistance of a new BCR::ABL1 p.I293_K294insSSLRD mutant detected in a Ph + ALL patient},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-024-06142-8}
}
Kostenlos starten →